12-March-2026

The Target‑Therapy project is now entering a new phase as it evolves into the PHOENIX project, uniting Inserm and the University of Brest (France), the University of Siegen (Germany), and the University of Catania (Italy). This next step is supported by dedicated funding from Inserm through the 2025 edition of the Projet de recherche international (PRI) call.

This recognition reinforces the consortium’s scientific momentum and strengthens its capacity to secure additional competitive fundings, including a proposal currently under evaluation within the European Union’s OHAMR programme.

Tony LE GALL

INSERM Researcher

tony.legall@univ-brest.fr